Lyman Support Centers LLC. - (303) 591-1960 - Join our email list!

Address; 800 W. 8th Ave #110 Denver Colorado - 2-6:45 PM Tuesday - Saturday

- Darren Lyman - (303) 591-1960 - Twitter | Facebook | LinkedIn

Medical Conditions Psilocybin Mushrooms May Help:

Evidence:

•Psilocybin induces rapid and sustained reductions in depression symptoms.

•In randomized controlled trials, psilocybin outperformed traditional antidepressants for treatment-resistant depression.

Key Study:

•Carhart-Harris et al., 2021 (NEJM)

“Psilocybin-assisted therapy showed efficacy comparable to escitalopram but with faster onset and emotional reconnection.”

Treatment-Resistant Depression (TRD)

Evidence:

•TRD patients report significant symptom reduction after psilocybin-assisted therapy, lasting weeks to months.

Key Study:

•Davis et al., 2021 (JAMA Psychiatry)

“71% of participants had >50% reduction in depression severity after psilocybin treatment.”

Post-Traumatic Stress Disorder (PTSD)

Evidence:

•Psilocybin promotes emotional flexibility and fear extinction via 5-HT2A receptor agonism.

•Encourages trauma processing and neuroplasticity.

Key Study:

•Krediet et al., 2020 (Front Psychiatry)

“Preliminary evidence supports psilocybin’s role in trauma therapy due to its ability to disrupt maladaptive neural patterns.”

Obsessive-Compulsive Disorder (OCD)

Evidence:

•Psilocybin reduces compulsive behavior and obsessive thoughts by resetting serotonergic pathways.

Key Study:

•Moreno et al., 2006 (Journal of Clinical Psychiatry)

“Psilocybin produced acute reductions in OCD symptoms with no adverse events in a pilot trial.”

Substance Use Disorders (Alcohol & Tobacco Addiction)

Evidence:

•Psilocybin shows high efficacy in reducing alcohol misuse and cigarette dependence via mystical-type experiences and neuroplastic resets.

Key Studies:

•Bogenschutz et al., 2015 (Journal of Psychopharmacology): “Psilocybin led to significant reductions in alcohol use.”

•Johnson et al., 2014 (Journal of Psychopharmacology): “80% smoking cessation rate at 6-month follow-up after psilocybin therapy.”

Cluster Headaches (Trigeminal Autonomic Cephalalgia)

Evidence:

•Psilocybin and LSD can prevent cluster headache cycles, likely through serotonin modulation.

Key Study:

•Sewell et al., 2006 (Neurology)

“Psilocybin aborted cluster headaches and extended remission in 7 out of 8 participants.”

Cancer-related Existential Distress & Anxiety

Evidence:

•Psilocybin reduces end-of-life anxiety, depression, and fear of death in terminal cancer patients.

Key Studies:

•Griffiths et al., 2016 (Journal of Psychopharmacology)

•Ross et al., 2016 (Journal of Psychopharmacology)

“80% of patients experienced significant reductions in anxiety and depression that lasted 6 months.”

Postpartum Depression (PPD)

Evidence:

•Though direct clinical trials are limited, psilocybin’s effects on depression, emotional reconnection, and neuroplasticity may benefit PPD.

Supporting Study:

•Davis et al., 2021 (JAMA Psychiatry)

•Griffiths et al., 2016 (Journal of Psychopharmacology)

Neurodegenerative Diseases (MS, ALS, Alzheimer’s, Parkinson’s – Theoretical Applications)

Evidence:

•Psilocybin promotes neurogenesis and dendritic spine growth in preclinical models, which may have protective roles in neurodegenerative conditions.

Key Study:

•Shao et al., 2021 (Neuron)

“Single-dose psilocybin increased dendritic spine density and structural plasticity.”

Anxiety Disorders & Generalized Anxiety Disorder (GAD)

Evidence:

•Psilocybin reduces rumination and promotes emotional acceptance in anxiety disorders.

Key Study:

•Griffiths et al., 2016

“Long-term reductions in anxiety observed after a single psilocybin session.”

References

1.Carhart-Harris et al., 2021. Psilocybin vs Escitalopram for Depression. NEJM.

https://www.nejm.org/doi/full/10.1056/NEJMoa2032994

2.Davis et al., 2021. Psilocybin Therapy for Depression. JAMA Psychiatry.

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2772630

3.Krediet et al., 2020. Psychedelics for PTSD. Front Psychiatry.

https://www.frontiersin.org/articles/10.3389/fpsyt.2020.00582/full

4.Moreno et al., 2006. Psilocybin for OCD. Journal of Clinical Psychiatry.

https://pubmed.ncbi.nlm.nih.gov/16490544/

5.Bogenschutz et al., 2015. Psilocybin for Alcohol Use Disorder.

https://journals.sagepub.com/doi/10.1177/0269881114565144

6.Johnson et al., 2014. Psilocybin for Tobacco Addiction.

https://journals.sagepub.com/doi/10.1177/0269881114548296

7.Sewell et al., 2006. Psilocybin for Cluster Headaches. Neurology.

https://n.neurology.org/content/66/12/1920

8.Griffiths et al., 2016. Psilocybin for Cancer Anxiety. Journal of Psychopharmacology.

https://journals.sagepub.com/doi/10.1177/0269881116675513

9.Ross et al., 2016. Psilocybin for Existential Distress.

https://journals.sagepub.com/doi/10.1177/0269881116675512

10.Shao et al., 2021. Psilocybin and Structural Neuroplasticity. Neuron.

https://www.cell.com/neuron/fulltext/S0896-6273(21)00606-2

Thanks for reading and sharing! Call or text anytime.

800 W. 8th Ave #110 Denver Colorado - (303) 591-1960 - Join our email list!